Current Trends in Manufacturing for Large Volume Parenteral in the Pharmaceutical Industry and Future Scopes
Faculty Mentor
Ahmed Abu Fayyad
Major/Area of Research
Pharmacy (Industry Pharmacy)
Description
INTRODUCTION: Large Volume Parenterals (LVPs) are manufactured in a number of steps, starting with the reception of excipients and Active Pharmaceutical Ingredients (API) and ending with the product's final shipment. A number of difficulties occur during these phases, including as manufacturing faults, sample errors, and problems with quality control. To guarantee the quality and safety of the final product, those working on various stages of production must also follow strict guidelines. In addition to implementing Good Manufacturing Practices (GMP) and other industry standards, the pharmaceutical sector is focusing more on production-related concerns like quality assurance and workforce management.
METHODS: The main components of LVP manufacturing are examined in this study, with particular attention paid to the importance of human interaction, automation, and the technologies now in use to guarantee product quality. It specifically covers the use of advanced technology in production, the implementation of GMP, and the integration of quality control procedures. The future of automation in LVP manufacturing is also covered in the study, along with possible effects on control systems, production, and quality assurance. RESULTS: According to the analysis, automation in a number of LVP manufacturing processes might greatly lower human error, improve product uniformity, and expedite production. The implementation of automated systems will improve the overall quality of the products by concentrating on lowering human dependency in areas like quality assurance and control. Furthermore, the functions of the quality assurance and manufacturing teams are essential to guaranteeing efficient production and legal compliance.
CONCLUSION: There will likely be a change toward increased automation in LVP manufacturing in the future. This change has the potential to improve product quality and save labor expenses. But it also calls for more study and advancement of automated systems, particularly in the fields of control and quality assurance. Future developments will help the pharmaceutical sector better handle the difficulties of mass production while enhancing the efficacy and safety of its products.
Current Trends in Manufacturing for Large Volume Parenteral in the Pharmaceutical Industry and Future Scopes
INTRODUCTION: Large Volume Parenterals (LVPs) are manufactured in a number of steps, starting with the reception of excipients and Active Pharmaceutical Ingredients (API) and ending with the product's final shipment. A number of difficulties occur during these phases, including as manufacturing faults, sample errors, and problems with quality control. To guarantee the quality and safety of the final product, those working on various stages of production must also follow strict guidelines. In addition to implementing Good Manufacturing Practices (GMP) and other industry standards, the pharmaceutical sector is focusing more on production-related concerns like quality assurance and workforce management.
METHODS: The main components of LVP manufacturing are examined in this study, with particular attention paid to the importance of human interaction, automation, and the technologies now in use to guarantee product quality. It specifically covers the use of advanced technology in production, the implementation of GMP, and the integration of quality control procedures. The future of automation in LVP manufacturing is also covered in the study, along with possible effects on control systems, production, and quality assurance. RESULTS: According to the analysis, automation in a number of LVP manufacturing processes might greatly lower human error, improve product uniformity, and expedite production. The implementation of automated systems will improve the overall quality of the products by concentrating on lowering human dependency in areas like quality assurance and control. Furthermore, the functions of the quality assurance and manufacturing teams are essential to guaranteeing efficient production and legal compliance.
CONCLUSION: There will likely be a change toward increased automation in LVP manufacturing in the future. This change has the potential to improve product quality and save labor expenses. But it also calls for more study and advancement of automated systems, particularly in the fields of control and quality assurance. Future developments will help the pharmaceutical sector better handle the difficulties of mass production while enhancing the efficacy and safety of its products.